IGC Pharma, Inc.
Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.
IGC | NYSE
Overview
Corporate Details
- ISIN(s):
- US45408X3089
- LEI:
- Country:
- United States of America
- Address:
- 10224 FALLS ROAD, 20854 POTOMAC
- Website:
- https://igcpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
IGC Pharma, Inc. is a clinical-stage pharmaceutical company dedicated to developing novel therapies for Alzheimer's disease. The company's lead candidate, IGC-AD1, is a cannabinoid-based investigational therapy in a Phase 2 clinical trial (CALMA) for treating agitation associated with Alzheimer's. IGC Pharma's pipeline also includes TGR-63, a small molecule designed to inhibit amyloid plaque aggregation. Complementing its therapeutic development, the company utilizes MINT-AD, a proprietary AI-powered platform that leverages multimodal data to support early disease detection and monitor progression. This dual approach of developing advanced therapeutics and AI-driven diagnostic tools positions IGC Pharma at the forefront of Alzheimer's research and care.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all IGC Pharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for IGC Pharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for IGC Pharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
